Lundbeck adds more data to successful migraine study of new candidate
Initially, Lundbeck is planning a phase II-b study which is scheduled to start early next year.
By marketwire
Pharmaceutical company Lundbeck has released more data from its successful phase II study, Hope, which investigated drug candidate Lu AG09222’s ability to prevent migraines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
